Controversy

Does ACR TI-RADS reliably triage thyroid nodules to biopsy better than alternatives?

Evidence profile

Status: awaiting_review. Rule: atlas-profile-2.0.

3 linked publications; not a count of independent studies.

Missing appraisal does not mean no evidence exists. Inspect the full profile and source relationships in the interactive Atlas.

Historical grade: WEAK (retained from 22 September 2026; not a completed profile 2.0 assessment).

Position A

Meta-analyses support ACR TI-RADS; it reduces unnecessary FNA while maintaining malignancy detection

Position B

Interobserver variability in feature scoring persists, systems (ACR/ATA/K-TIRADS) disagree, and performance varies by population

Clinical stakes

Determines which nodules get biopsied; over-call drives unnecessary FNA, under-call misses cancer.

Open in the interactive atlas →

About this page

Curated and maintained by Resonant Labs. Editorial lead: E. Brooke Schrickel, M.D. Claims are synthesized from the cited literature and graded per the Atlas methodology (about the Atlas). Page generated 2026-10-02. This is not a new clinical review date.

This is an educational research resource from Resonant Labs, not clinical advice. Atlas assessments are heuristic, not probabilities or formal GRADE ratings. Findings are summarized from the literature and may change as the field evolves.